24 Nov 2017 | 11:22 AM


Aurobindo gets USFDA nod for mucus treatment drug
Published on 03-20-2017
Pharma major Aurobindo Pharma Ltd on Monday said it has received final nod from the US health regulator to manufacture mucus treatment drug.

“The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture guaifenesin and dextromethorphan hydrobromide extended-release tablets 600/30m g and 1200/60 mg (OTC)” Aurobindo Pharma Ltd said in a filing to the Bombay Stock Exchange on March 20 2017.

The company’s said drug is the AB rated generic equivalent of Reckitt Benckiser’s Mucinex DM tablets it said.

It further said that the product will be launched in Q1FY18.

The said tablets help loosen mucus and phlegm and thin out bronchial secretions making coughs more productive.

Moreover the approved product has an estimated market size of USD 235 million for the twelve months ending December 2016 according to IRI database.

Meanwhile shares of the company closed at Rs 703.20 apiece up 2.38 per cent from previous close on BSE.